Employees: 649
Size Sino Medical Sciences Technology (688108.SS) is a China Health Care company (Medical Specialties) with a market value of $753M, the 2716th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.16 on 18 Nov 2026.
Performance Over six months the shares fell 41.1%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 22.0% over the last twelve months (peer median +9.1%); the operating margin is 19.2% (peer median 12.7%).
Valuation It trades at 60.0× forward earnings against a peer median of 19.9× (2nd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points above its cost of capital (14.1% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥611M | CN¥519M | CN¥455M | CN¥341M | CN¥192M |
| Revenue growth | — | +14% | +33% | +78% | — |
| Gross profit | CN¥444M | CN¥281M | CN¥210M | CN¥142M | CN¥54.2M |
| EBITDA | n/a | CN¥142M | CN¥57.4M | CN¥12.9M | -CN¥135M |
| Net income | CN¥95.3M | CN¥47.3M | CN¥1.50M | -CN¥39.6M | -CN¥162M |
| Free cash flow | CN¥193M | CN¥116M | CN¥61.3M | -CN¥10.5M | -CN¥221M |
| Capital expenditure | CN¥29.6M | CN¥45.8M | CN¥70.0M | CN¥67.7M | CN¥111M |
| Total debt | CN¥147M | CN¥130M | CN¥225M | CN¥199M | CN¥58.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688108.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.1% | -6.7% | 9th lowest of 21 |
| 6-month return | -41.1% | -13.5% | 2nd lowest of 21 |
| Distance from 52-week high | -53.7% | -39.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +22.0% | +9.1% | 8th highest of 21 |
| Operating margin | 19.2% | 12.7% | 3rd highest of 21 |
| Forward P/E | 60.0× | 19.9× | 2nd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 27.9% | 3.8% | most demanding of 14 |
| Growth delivered (Del g) | +9.9% | +13.2% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | +18.0 pp | -9.8 pp | 3rd most demanding of 14 |
| ROIC minus cost of capital | +1.6 pp | -0.3 pp | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 60.0× | 27.9% | +9.9% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | n/a | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 55.4× | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $710M | -22% | +6% | 14% | 22.8× | -3.4% | +15.7% |
| SWS Hemodialysis Care 688410.SS | China | $706M | -11% | +31% | 19% | 23.5× | 16.2% | +25.9% |
| Japan Lifeline 7575.T | Japan | $703M | +34% | +6% | 19% | 14.5× | -9.5% | +2.9% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |